Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 3-4/2007

01-12-2007

Myocardial protection in man—from research concept to clinical practice

Authors: Dennis V. Cokkinos, Costas Pantos

Published in: Heart Failure Reviews | Issue 3-4/2007

Login to get access

Abstract

Myocardial protection aims at preventing myocardial tissue loss: (a) In the acute stage, i.e., during primary angioplasty in acute myocardial infarction. In this setup, the attenuation of reperfusion injury is the main target. As a “mechanical” means, post-conditioning has already been tried in man with encouraging results. Pharmacologic interventions that could be of promise are statins, insulin, peptide hormones, including erythropoietin, fibroblast growth factor, and many others. (b) The patient with chronic coronary artery disease offers another paradigm, with the target of avoidance of further myocyte loss through apoptosis and inflammation. Various pharmacologic agents may prove useful in this context, together with exercise and “mechanical” improvement of cardiac function with attenuation of myocardial stretch, which by itself is a noxious influence. A continuous effort toward acute and chronically preserving myocardial integrity is a concept concerning both the researcher and the clinician.
Literature
1.
Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in isxhemic myocardium. Circulation 75:1124–1136
2.
Arrell DK, Elliott ST, K-ane LA, Guo Y, Ko YH, Pedersel PL, Robinson J, Murata M, Murphy AM, Marban E, Van Eyk JE (2006) Proteomic analysis of pharmacological preconditioning. Novel protein targets converge to mitochondrial metabolism pathways. Circ Res 99:706–714PubMed
3.
Cohen RA, McComb ME (2006) Preconditioning enters the era of “physiological proteomics”. Circ Res 99:663–665PubMed
4.
Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP, Kubler W, Katus HA, Vogt AM (2006) Myocardial preconditioning and remote renal preconditioning. Identifying a protective factor using proteomic methods? Basic Res Cardiol 101:149–158PubMed
5.
Heusch G (2001) Nitroglycerin and delayed preconditioning in humans. Circulation 103:2876–2878PubMed
6.
Barbash GI, White HD, Modan M, Van de Werf F (1992) Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 20:6–41CrossRef
7.
Ottani F, Galvani M, Ferrini D (1998) Angina and Cardiac adaptation. In: Baxter GF, Yellon DM (eds) Delayed preconditioning and adaptive cardioprotection. Kluwer Academic Publishers, Dordrecht, pp 209–224
8.
Arslanian-Ergoren C, Patel A, Fang j, Armstrong D, Kline-Rogers E, Duvernoy CS, Eagle KA (2006) Symptoms of men and women presenting with acute coronary syndromes. Am J Cardiol 98:1177–1181
9.
Cokkinos AD, Tzeis S, Moraitis P, Pantos C, Carageorgiou H, Panousopoulos D, Varonos DD, Cokkinos DV (2003) Loss of cardioprotection induced by ischemic preconditioning after an initial ischaemic period in isolated rat hearts. Exp Clin Cardiol 8:5–9PubMed
10.
Tani M, Honma Y, Hasegawa H, Tamaki K (2001) Direct activation of mitochondrial KATP channels mimics preconditioning but protein kinase C activation is less effective in middle-aged rat hearts. Cardiovasc Res 49:56–68PubMed
11.
Boengler K, Heusch G, Schulz R (2006) Connexin 43 and ischemic preconditioning: effects of age and disease. Exp Gerontol 41:485–488PubMed
12.
Baker EJ Boerboom LE, Olinger GN, Baker JE (1995) Tolerance of the developing heart to ischemia: impact of hypoxemia from birth. Am J Physiol 268:H1165–1173
13.
Iwaki K, Chi S, Dillmann WH, Mestril R (1993) Induction of HSP70 in cultured rat neonatal cardiomyocytes by hypoxia and metabolic stress. Circulation 87:2023–2032PubMed
14.
Baker JE, Holman P, Gross GJ (1999) Preconditioning in immature rabbit hearts: Role of KATP channels. Circulation 99:1249–1254PubMed
15.
Awad WI, Shattock MJ, Chambers DJ (1998) Ischemic preconditioning in immature myocardium. Circulation 98:II-206–II-213
16.
Ravingerova T, Neckar J, Kolar F, Stetka R, Volkovova K, Ziegelhöffer A, Styk J (2001) Ventricular arrhythmias following coronary artery occlusion in rats: is the diabetic heart less or more sensitive to ischaemia? Basic Res Cardiol 96:160–168PubMed
17.
Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A (2004) Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47:1716–1721PubMed
18.
Katakam PV, Jordan JE, Snipes JA, Tlbert CD, Miller AW, Busija DW (2006) Myocardial preconditioning against ischemia-reperfusion injury is abolished in zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol Sept. 28
19.
Thim T, Bentzon JF, Kristiansen SB, Simonsen U, Andersen HL, Wassermann K, Falk E (2006) Size of myocardial infarction induced by ischaemia-reperfusion is unaltered in rats with metabolic syndrome. Clin Sci 110:665–671PubMed
20.
Szekeres L, Szilvassy Z, Ferdinandy P, Nagy I, Karscu S, Csati S (1997) Delayed cardiac protection against harmful consequences of stress can be induced in experimental atherosclerosis in rabbits. J Mol Cell Cardiol 29:1977–83PubMed
21.
Kremastinos D, Bofilis E, Karavolias G, Papalois A, Kaklamanis L, Iliodromitis E (2000) Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. Atherosclerosis 150:81–85PubMed
22.
Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Tzeis SM et al (2001) Long-term thyroxine administration increases HSP70 mRNA expression and attenuates p38MAP kinase activity in response to ischaemia. J Endocrinol 170:207–215PubMed
23.
Pantos C. Malliopoulou V, Mourouzis I, Karamanoli E, Paizis I, Steinberg N et al (2002) Long-term thyroxine administration protects the heart in a similar pattern as ischaemic preconditioning. Thyroid 12:325–329
24.
Zhao J, Renner O, Wightman L, Sugden PH, Stewart L, Miller AD, Latchman DS, Marber MS (1998) The expression of constitutively active isotypes of protein kinase C to investigate preconditioning. J Biol Chem 273:23072–23079PubMed
25.
Goldenthal MJ, Weiss HR, Marin-Garcia J (2004) Bioenergetic remodelling of heart mitochondria by thyroid hormone. Mol Cellular Biochem 265:97–106
26.
Salter D, Dyke C, Wechsler A (1992) Triodothyronine (T3) and cardiovascular therapeutics: a review. J Card Surg 4:363–374
27.
Moruzzi P, Doria E, Agostoni PG, Capacchione V, Saganzerla P (1994) Usefulness of l-thyroxine to improve cardiac, and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 73:374–378PubMed
28.
Moruzzi P, Doria E, Agostoni PG (1996) Medium term effectiveness of l-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101:461–467PubMed
29.
Mahaffay KW, Raya T, Pennock G, Morkin E, Goldman S (1995) Left ventricular performance and remodelling in rabbits after myocardial infarction: effects of a thyroid hormone analogue. Circulation 91:794–801
30.
Ojamaa K, Kenessey A, Shenoy R, Klein I (2000) Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab 279:E1319–1324PubMed
31.
Friberg L, Drvota V, Bjelak AH (2002) Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. Arch Intern Med 162:1388–1394PubMed
32.
Iervasi G, Pinagitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L´Abbate A, Donato L (2003) Low T3 syndrome. Circulation 107:708–713PubMed
33.
Hamilton MA, Stevenson LW, Luu M, Walden JA (1990) Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16:91–95PubMedCrossRef
34.
Psirropoulos D, Lefkos N, Boudonas F, Efthimiadis A, Vogas V, Keskilidis C, Tsapas G (2002) Heart failure accompanied by sick euthyroid syndeome and exercise training. Curr Opinion Cardiol 17:266–270
35.
Suzuki Y, Nanno M, Gemma R, Yoshimi T (1992) Plasma free fatty acids, inhibitor of extrathyroidal conversion of T4 to T3 and thyroid hormone binding inhibitor in patients with various nonthyroidal illness. Endocrinol Jpn 39:445–453PubMed
36.
Novitzky D, Cooper DK, Swanepoel A (1989) Inotropic effect of triiodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: an initial experience in patients undergoing open heart surgery. Eur J Cardiothotac Surg 3:140–145
37.
Mackie A, Booth K, Newburger J et al (2005) A randomized, double-blinded, placebo-controlled trial of tri-iodothyronine in neonatal heart surgery (Abstr.). J Am Coll Cardiol 45:321A
38.
Ranasinghe A, Quinn D, Pagano D, Edwards N, Faroqui M, Graham T Keogh B, Mascaro J, Riddington D, Rooney S, Townend J, Wilson I (2006) Bosner R. Glucose-Insulin-Potassium and Tri-Iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Crirculation 114:I-245–250
39.
Kimura T, Kanda T, Kuwabara A, Shinohara H, Kobayashi I (1997) Participation of the pituitary-thyroid axis in the cardiovascular system in elderly patients with congestive heart failure. J Med 28:75–80PubMed
40.
Blumgart HL, Freedberg AS, Kurland GS (1957) Radioactive iodine treatment of antina pectoris and congestive heart failure. Circulation 16:110–118PubMed
41.
Gomberg-Maitland M, Frishman WH (1998) Thyroid hormone and cardiovascular disease. Am Heart J 135:187–196PubMed
42.
Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, Stamatelopoulos S, Koutras DA (1997) Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 7:411–414PubMedCrossRef
43.
Pantos CI, Tzilalis V, Giannakakis S, Cokkinos DD, Tzeis SM et al (2001) Phenylephrine induced aortic vasoconstriction is attenuated in hyperthyroid rats. Int Angiol 20:181–186PubMed
44.
Pantos C. Malliopoulou V, Mourouzis I et al (2003) Propylthiouracil induced hypothyroidism is associated with increased tolerance of the isolated rat heart to ischaemia-reperfusion. J Endocrinol 178:427–735
45.
Apstein CS, Menasche P, Lorell BH (1990) Hypoxia, ischaemia, and the hypertrophied myocardium: basic medical and surgical considerations. In: Swynghedauw B (ed). Cardiac hypertrophy and failure. Editions INSERM, Paris, pp 65–87
46.
Cooley DA, Reul GJ, Wukash DC (1972) Ischemic contracture of the heart “stone heart”. Am J Cardiol 29:575–577PubMed
47.
Schaper J, Schwarz F, Flameng W, Hehrlein F (1978) Tolerance to ischemia of hypertrophied human hearts during valve replacement. Basic Res Cardiol 73:171–187PubMed
48.
Marcus ML, Koyanagi S, Harrison DG, Doty DB, Hiratzka LF, Eastham CL (1983) Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med 75:62–66PubMed
49.
Speechly-Dick ME, Baxter GF, Yellon DM (1994) Ischemic preconditioning protects hypertrophied myocardium. Cardiovasc Res 28:1025–1029PubMed
50.
Pantos CI, Davos CH, Carageorgiou HC, Varonos DV, Cokkinos DV (1996) Ischaemic preconditioning protects against myocardial dysfunction caused by ishaemia in isolated hypertrophied rat hearts. Basic Res Cardiol 91:444–449PubMed
51.
Miki T, Miura T, Tsuchiada A, Nakano A, Hasegawa T, Fukuma T, Shimamoto K (2001) Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type receptor activation. Circulation 102:458–463
52.
Ghosh S, Standen NB, Galinanes M (2001) Failure to precondition pathological human myocardium. J Am Coll Cardiol 37:711–718PubMed
53.
Efstathiou A, Seraskeris S, Papakonstantinou C, Aidonopoulos A, Lazou A (2001) Differential effect of preconditioning on post-ischaemic myocardial performance in the absence of substantial infarction and in extensively infarced rat hearts. Eur J Cardiothorac Surg 19:493–499PubMed
54.
Shimohama T, Suzuki Y, Noda C, Niwano H, Sato K, Masuda T, Kawahara K, Izumi T (2002) Decreased expression of Na+/H+ exchanger isoform 1 (NHE1) in non-infarced myocardium after acute myocardial infarction. Jpn Heart J 43:273–282PubMed
55.
Pantos C, Mourouzis I, Saranteas T, Paizis I, Xinaris Ch, Malliopoulou V, Cokkinos DV (2005) Thyroid hormone receptors α and β1 are downregulated in the post-infarcted rat heart:consequences on the response to ischaemia-reperfusion. Basic Res Cardiol 100:422–432PubMed
56.
Murray AJ, Lygate CA, Cole MA, Carr CA, Radda GK, Neubauer S, Clarke K (2006) Insulin resistace, abnormal energy metabolism and increased ischemic damage in the chronically infracted rat heart. Cardiovasc Res 71:149–157PubMed
57.
Heusch G (2004) Postconditioning. Old wine in a new bottle? Editorial. J Am Coll Cardiol 44:1111–1112PubMed
58.
Kin H, Zhao Z-Q, Sun H-Y, Wang N-P, Corvera JS, Halkos ME, Kerandi F, Guyton RA, Vinten-Johansen J (2004) Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62:79–85
59.
Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S, Gattullo D, Losano G, Pagliaro P (2006) Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP- sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 101:180–189PubMed
60.
Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D, Losano G, Pagliaro P (2006) Post-conditioning reduces infarct size in the isolated rat heart: role ofcoronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 101:168–179PubMed
61.
Iliodromitis E, Georgiadis M, Cohen M, Downey J, Bofilis E, Kremastinos DT (2006) Protection from postconditioning depends on the number of short ischemic insults in anesthetized pigs. Basic Res Cardiol 101:502–507PubMed
62.
Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M (2005) Postconditioning the Human Heart. Circulation 112:2143–2148PubMed
63.
Mickel HS, Vaishnav YK, Kempski O, von Lubitz D, Weiss JF, Feuerstein G (1987) Breathing 100% oxygen after global brain ischemia in Mongolian gerbils redults in increased lipid peroxidation and increased mortality. Stroke 18:426–430PubMed
64.
Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M (1999) Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J Exp Med 189:1699–1706PubMed
65.
Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS (2003) Exercise – induced ischemia initates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol 41:1174–1182PubMed
66.
Kelion AD, Webb TP, Gardner MA (2001) The warm-up effect protects against ischemic left ventricular dysfunction in patients with angina. J Am Coll Cardiol 37:705–710PubMed
67.
Konstantinov I, arab S, Li J, Goles J, Boscarino C, Mori A, Cukerman E, Dawood F, cheung M, Shimizu M, Liu P, Redington A (2005) The remote ischemic preconditioning stimulus modifies gene expression in mouse myocardium. J Thorac Cardiovasc Surg 130:1326–1332PubMed
68.
Kudej R, Shen Y-T, Peppas A, Huang C-H, Chen W, Yan L, Vatner D, Vatner S (2006) Obligatory role of cardiac nerves and α1-adrenergic receptors for the second window of ischemic preconditioning in conscious pigs. Circ Res 99:1270–1276PubMed
69.
Przyklenk K, Darling CE, Dickson EW, Whittaker P (2003) Cardioprotection « outside the box ». Basic Res Cardiol 98:149–157PubMed
70.
Yellon DM, Alkulaifi AM, Pugsley WB (1993) Preconditioning the human myocardium. Lancet 342:276–277PubMed
71.
Szmagala P, Gbure KT, Morawski N et al (1999) A clinical assessment of ischemic preconditioning for aorto-coronary bypass surgery. Cor Europaeum 7:107–111
72.
Verma S, Fedak PW, Weisel RD, Szmitko PE, Badiwala MV, Bonneau D, Latter D, Errett L, LeClerc Y (2004) Off-pump coronary artery bypass surgery: fundamentals for the clinical cardiologist. Circulation 109:1206–1211PubMed
73.
Liu GS, Thornton J, van Winkle DM, Stanely AWH, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84:350–356PubMed
74.
Zhao TC, Hines DS, Kukreja RC (2001) Adenosine-induced late precondition in mouse hearts: role of p38 MAP kinase and mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 280: H1278–1285PubMed
75.
Heidland UE, Heintzen MP, Schwartzkopff B, Strauer BE (2000) Preconditioning during percutaneous transluminal coronary angioplasty by endogenous and exogenous adenosine. Am Heart J 140:813–820PubMed
76.
Lee C-H, Low A, Tai B-C et al (2007) Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous intervention: a prospective randomized study. Eur Heart J 28:19–25PubMed
77.
Claeys MJ, Vrints CJ, Bosmans JM, Conraads VM, Snoeck JP (1996) Aminophylline inhibits adaptation to ischemia during angioplasty. Eur Heart J 17:539–544PubMed
78.
Risken N, Zhou Z, Oyer W, Jaspers R, Ramakers B, Brouwer R, Boerman O, Steinmetz N, Smits P, Rongen G (2006) Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 48:700–707
79.
Grover GJ, Garlid KD (2000) ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 32:677–695PubMed
80.
Cleveland JC, Meldrum DR, Cain VS, Banerjee A, Harken A (1997) Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96:29–32PubMed
81.
Brady P, Terzie A (1998) The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 31:950–956PubMed
82.
Wang H, Long C, Duan Z et al (2007) A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res 73:497–503PubMed
83.
Auchampach JA, Maruyama M, Gross GJ (1994) Cardioprotective actions of potassium channel openers. Eur Heart J 15:C81–84
84.
O´Rourke B (2000) Mitochondrial KATP channels in preconditioning. Circ Res 87:845–855
85.
Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63:18J–24JPubMed
86.
Iliodromitis EK, Cokkinos P, Zoga A, Steliou I, Vrettou AR, Kremastinos DT (2003) Nicorandil recaptures the waned protection from preconditioning in vivo. Br J Pharmacol 138:1101–1106PubMed
87.
Lee T-M, Su S-F, Chou T-F, Lee YT, Tsai C-H (2002) Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 105:334–340PubMed
88.
The IONA study group (2002) Effect of nicorandil on coronary events in patients with stable angina: The impact of Nicorandil in Angina (IONA) randomized trial. Lancet 359:1269–1267
89.
Johansen D, Ytrehus K, Baxter G (2006) Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury. Evidence for a role of K ATP channels.Basic Res Cardiol 101:53–60
90.
Tang G, Wu L, Liang W, Wang R (2005) Direct stimulation of KATP channels by exogenous and endogenous hydrogen sulphide in vascular sooth muscle. Mol Pharmacol 68:1757–1764PubMed
91.
Stipanuk MH (2004) Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nuitr 24:539–577
92.
Zeymer U, Suryapranata H, Monassier JP et al (2001) The Na+/Ca2+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safery and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI trial). J Am Coll Cardiol 38:645–650
93.
Buerke M, Rupprecht H-J, vom Dahl J, Terres W, Seyfurth M, Schultheiss H-P, Richardt G, Sheehan FH, Dexlet H (1999) Sodium-hydrogen exchange inhibition : Novel strategy to prevent myocardial injury following ischemia and reperfusion. Am J Cardiol 83:19G–22GPubMed
94.
Piper HM, Abdallah Y, Schäfer C (2004) The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61:365–371PubMed
95.
Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R (2001) Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 103:2876–2878
96.
Heusch G (2001) Nitroglycerin and delayed preconditioning in humans. Circulation 103:2876–2878PubMed
97.
Hasdai D, Behar S, Wallentin L. Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A (2002) A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. Eur Heart J 23:1190–1201PubMed
98.
Sbarouni E, Iliodromitis EK, Bofilis E, Kyriakides ZS, Kremastinos DT (1998) Short-term estrogen reduces myocardial infarct size in oophororectomized female rabbits in a dose-dependent manner. Cardiovasc Drugs Ther 12:457–462PubMed
99.
Ogita H, Node K, Asanuma H, Sanada S, Liao Y, Takashima S, Asakura M, Mori H, Shizonaki Y, Hori M, Kitakazo M (2002) Amelioration of ischemia and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardol 40:998–1005
100.
Sbarouni E, Iliodromitis EK, Bofilis E, Kyriakides ZS, Kremastinos DT (2003) Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol 467:163–168PubMed
101.
English KM, Jones RD, Jones TH, Morice AH, Channer KS (2002) Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 25:455–458PubMed
102.
Callils F, Stromer H, Schwinger RH, Bolck B, Hu K, Frantz S, Leupold A, Beet S, Allolio B, Bonz AM (2003) Administration of testosterone is associated with a reduced susceptibility to myocardial ischemia. Endocrinology 144:4478–4483
103.
Malkin C, Pugh P, West J, van Beek E, Jones TH, Channer KS (2006) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57–64PubMed
104.
Diel P, Friedel A, Geyer H et al (2007) Characterisation of the pharmacological profile of desoxymethyltestosterone (Madol), a steroid misused for doping. Toxicol Lett 169:64–71PubMed
105.
Fischer-Rasokat U, Beyersdorf F, doenst T (2003) Insulin addition after ischemia improves recovery of function equal to ischemic preconditioning in rare heart. Basic Res Cardiol 98:329–336PubMed
106.
Podesser BK, Schirnhofer J, Bern3ecker OY, Kröner A, Franz M, Semsroth S, Fellner B, Neumüller J, Hallström S, Wolner E. (2002) Optimizing ischemia/reperfusion in the failing rat heart-improved myocardial protection with acute ACE inhibition. Circulation 106(Suppl I):277–283
107.
Leesar M, Stoddard MF, Manchikalapudi S, Bolli R (1999) Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 34:639–650PubMed
108.
Schwarz ER, Montino H, Fleischhauer J, Klues HG, vom Dahl J, Hanrath P (1997) Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditionng in the pig heart. Cardiovasc Drugs Ther 11:687–695PubMed
109.
Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K (1999) Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovasc Drugs Ther 13:151–157PubMed
110.
Jaberansari MT, Baxter GF, Muller CA, Latouf SE, Röth E, Opie LH, Yellon DM (2001) Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. J Am Coll Cardiol 37:1996–2001PubMed
111.
Bartling B, Friedrich I, Silber RE, Simm A (2003) Ischemic preconditioning is not cardioprotective in senescent human myocardium. Ann Thorac Surg 76:105–111PubMed
112.
Hayakawa K, Takemura G, Kanoh M, Li Y, Koda M, Kawase Y, Marwyama R, Okada H, Minatoguchi S, Fujiwara T, Fujiwara H (2003) Inhibition of granulation tissue cell apoptosis during the subacute stage of myocardial infarction improves cardiac remodeling and dysfunctio nat the chronic stage. Circulation 108:104–109PubMed
113.
Cargnoni A, Ceconi C, Bernocchi P, Boraso A, Parrinello G, Curello S, Ferrari R (2000) Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. Cardiovasc Res 47:556–566PubMed
114.
Yue TL, Ma XL, Gu R Ruffolo RR Jr, Feuerstein GZ (1998) Carvedilol inhibits activation of stress-activated protein kin and reduces reperfusion injury in perfused rabbit heart. Eur J Pharmacol 345:61–65PubMed
115.
Fan GC, Reu X, Qian J, Yuan Q, Nicolaou P, Wang Y, Jones WK, Chre G, Kranias EG (2005) Novel cardioprotective role of a small heart-shock protein, Hsp20, against ischemia/reperfusion injury. Circulation 111:1792–1799PubMed
116.
Gasser R, Frey G, Fleckenstein-Grün G, Byon YK, Fleckenstein A (1999) Some observations on Ca-overload in rat ventricular tissue. J Clin Basic Cardiol 2:255–258
117.
Daly MJ, Elz JS, Nayler WG (1985) The effect of verapamil on ischemia-induced changes to the sarcolemma. J Mol Cell Cardiol 17:667–674PubMed
118.
Inagaki K, Kihara Y, Izumi T, Sasayama S (2000) The cardioprotective effects of a new 1,4–benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload is isolated rat hearts. Cardiovasc Drug Ther 14:489–495
119.
Heusch G (1992) Myocardial stunning: a role for calcium antagonists during ischemia? Cardiovasc Res 26:14–19PubMed
120.
Garrett JS, Wikman-Coffelt J, Sievers R, Finkbeiner WE, Parmley WW (1987) Verapamil prevents the development of alcoholic dysfunction in hamster myocardium. J Am Coll Cardiol 9:1326–1331PubMedCrossRef
121.
Sievers R, Parmley WW, James T, Wikman-Coffelt J (1983) Energy levels at systole vs diastole in normal hamster hearts vs myopathic hamster hearts. Circ Res 53:759–766PubMed
122.
Koller PT, Bergmann SR (1989) Reduction of lipid peroxidation in reperfused isolated rabbit hearts by diltiazem. Circ Res 65:838–845PubMed
123.
McVeigh JJ, Lopaschuk GD (1990) Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 259:H1079–H1085PubMed
124.
Graslinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR (1994) Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 28:1231–1237
125.
Timmis AD, Chaitman BR, Crager M (2006) Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27:42–48PubMed
126.
Schmidt-Schweda S, Holubarsch C (2999) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 99:27–35
127.
Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P (1994) Trimetazidine: a new concept in the treatment of angina. Comparison with propranolon in patients with stable angina. Br J Clin Pharmacol 37:279–288PubMed
128.
Fabiani JN, Ponzio O, Emerit I, Massonet-Castel S, Paris M, Chevalier P, Jebara V, Carpentier A (1992) Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 33:486–491
129.
Mody FV, singh BN, Mohiuddin IH, Coyle KB, Buxton DB, Hansen HW, Sumida R, Schekber HR (1998) Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 82:42K–49KPubMed
130.
Pantos C, Bescond-Jacket A, Tzeis S et al (2004) Trimetazidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing-dependent manner. Basic Res Cardiol 99:1–7
131.
Cokkinos DV (2001) Can metabolic manipulation reverse myocardial dysfunction? Editorial Eur Heart J 22:2138–2139
132.
Di Napoli P, Taccardi AA, Barsotti A (2005) Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91:161–165PubMed
133.
Broderick TL, Quinney A, Barker C, Lopaschuk G (1993) Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 87:972–981PubMed
134.
Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J 139:S120–123PubMed
135.
Helton E, Darragh R, Francis P, Fricker J, Jue K, Koch G, Mair D, Pierpont ME, Prochazka JVLS, Winter SC (2000) Metabolic aspects of myocardial disease and a role for l-carnitine in the treatment of childhood cardiomyopathy. Pediatrics 105:1260–1270PubMed
136.
Iliceto S, Scrutinio D, Bruzzi P, D´Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz P, Rizzon P, on behalf of the CEDIM Investigators. (1995) Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: The L-carnitine ecocardiografia digitalizzata infarto miocardico (CEDIM) trial. J Am Coll Cardiol 26:380–387PubMed
137.
Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardol 26:57–65
138.
Van der Horst IC, Zijlstra F, van´t Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, Bilo HJ (2003) Swolle Infarct Study Group. Glucose-insulin potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomised trial. J Am Coll Cardiol 42:784–791PubMed
139.
Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS (2001) Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 14:615–623
140.
Chaudhuri A, Janicke D, Wilson MF, Tripaty D, Garg R, Bandypadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P (2004) Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109:849–854PubMed
141.
Bell RM, Yellon DM (2003) Atorvastatin administered at the onset of reperfusion, and independently of lipid lowering, protects the myocardium by up-regulating a prosurvival pathway. J Am Coll Cardiol 41:508–515PubMed
142.
Di Napoli P, Taccardi AA, Grilli A, Spina R, Felaco M, Barsotti A, De Caterina R (2001) Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex-vivo study in isolated working rat hearts. Cardiovasc Res 51:283–293PubMed
143.
Eaton P, Hearse DJ, Shattock MJ (2001) Lipid hydroperoxide modification of proteins during myocardial ischaemia. Cardiovasc Res 51:294–303PubMed
144.
Chen H, Li D, Roberts GJ, Saldeen T, Mehta JL (2003) Eicosipentanoic acid inhibits hypoxia-rexygenation-induced injury by attenuating upregulation of MMp–1 in adult rat muyocytes. Cardiovasc Res 59:7–13PubMed
145.
Coronel R, Wilms-Schopman FJG, Den Ruijter HM et al (2007) Dietary n–3 fatty acids promote arrhythmias during acute regional myocardial ischemia in isolated pig hearts. Cardiovasc Res 73:386–394PubMed
146.
Lee TM, Chou TF (2003) Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin 43 proteins. Am J Physiol. Heart Circ Physiol 285:H1650–1659PubMed
147.
Liu H-R, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135–144PubMed
148.
Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, hatterjee PK, Thiemermann C (2002) Ligands of the peroxisome proliferators-actibared receptors (PPAR-gamma and PPAR alpha) reduce myocardial infarct size. Faseb J 16:1027–1040PubMed
149.
Bulhak A, Sjoquist P-O, Xu C-B, Edvinsson L, Pernow J (2006) Protection against myocardial ischaemia-reperfusion injury by PPAR-α activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 101:244–252PubMed
150.
Cuzzocrea S, Mazzon E, Constantino G, Serraino I, De Sarro A, Caputi A (2000) Effects of n-acetylcysteine in rat model of ischemia and reperfusion injury. Cardiovasc Res 47:537–548PubMed
151.
Spargias K, Alexopoulos E, Kyrzopoulos S, Iakovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV (2004) Ascorbic acid prevents contrast-mediated nephropathy in patiens with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837–2842PubMed
152.
Nespereira B, Perez-Ilzarbe M, Fernandez P, Fuentes AM, Paramo JA, Rodriguez JA (2003) Vitamins C and E downregulate vascular VEGF and VEGFR–2 expression in apolipoprotein-E-deficient mice. Atherosclerosis 171:67–73PubMed
153.
Bolli R, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, Lai EK, McCay PB (1989) Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial “stunning” is a manifestation of reperfusion injury. Circ Res 65:607–622PubMed
154.
Paraskevaidis IA, Iliodromitis EK, Vlahakos D, Tsiapras DP, Nikolaids A, Marathias A, Michalis A, Kremastinos DT (2005) Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury : immediate and long-term significance. Eur Heart J 26:263–270PubMed
155.
Werns SW, Shea MJ, Mitsos SE, Dysko RC, Fantone JC, Schork A, Abrams GD, Pi HB, Lucchesi BR (1986) Reduction of the size of infarction by allopurinol in the ischemic-reperfused canine heart. Circulation 73:518–524PubMed
156.
Stull LB, Leppo MK, Szweda L, Gao D, Marban E (2001) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95:1005–1011
157.
Dobsak P, Siegelova J, Eicher JC, Jancik K, Svacinova H, Vascu J, Kuchtickova S, Horky M, Wolf JE (2003) Melatonin protect against ischemia-reperfusion injury and inhibits apoptosis in isolated working rat heart. Physiology 9:179–187
158.
Reiter RJ, Tan D-X (2003) Review. Melatonin: a nove protective agent against oxidative injury of the ischemia reperfused heart. Cardiovasc Res 58:10–19PubMed
159.
Hung L-M, Chen J-K, Huang S-S, Lee R-S, Su M-J (2000) Cardioprotective effect of resveratrol a natural antioxidant derived from grapes. Cardiovasc Res 47:549–555PubMed
160.
Anselm E, Chataigneau M, Ndiaye M et al (2007) Grape juice causes endothelium-dependent relaxation via a redox-sensitive Src-and Akt-dependent activation of eNOS. Cardiovasc Res 73:404–413PubMed
161.
Skyschally A, Schulz R, Gres P, Korth HG, Heusch G (2003) Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid. Am J Physiol Heart Circ 284:H648–703
162.
Peart JN, Gross GJ (2004) Morphine-tolerant mice exhibit a profound and persistant cardioprotective phenotype. Circulation 109:1219–1222PubMed
163.
Ko SH, Yu CW, Lee SK, Choe H, Chung MJ, Kwak YG, Chae SW, Song HS (1997) Propofol attenuates ischemic-reperfusion injury in the isolated rat heart. Anesth Analg 85:719–724PubMed
164.
Javadov SA, Lim KHH, Kerr PM, Suleiman S, Angelini GD, Halestrap AP (2000) Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc Res 45:360–369PubMed
165.
Weinbrenner C, Liu GS, Downey JM, Cohen MV (1998) Cyclosporine A limits infarct size even when administered after onset of ischemia. Cardiovasc Res 38:678–684PubMed
166.
Borutaite V, Jekabsone A, Morkuniene R, Brown GC (2003) Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome C release and apoptosis induced by heart ischemia. J Moll Cell Cardiol 35:357–366
167.
Brar BK, Stephanou A, Liao Z et al (2001) Cardiotrophin–1 can protect cardiac myocytes from injury when added both prior to simulated ischemia and at reoxygenation. Cardiovasc Res 51:265–274PubMed
168.
Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH (2001) Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104: I308–313PubMed
169.
Skyschally A, Gres P, Hoffman S et al (2007) Bidirectional role of tumor necrosis factor-a in coronary microembolization. Circ Res 100:140–146PubMed
170.
Du Toit EF, Muller CA, McCarthy J, Opie LH (1999) Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleatide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 290:505–514PubMed
171.
Pantos C, Mourouzis I, Tzeis S et al (2003) Dobutamine administration exacerbates postischemic myocardial dysfunction in isolated rat hearts; an effect reversed by thyroxine pre-treatment. Eur J Pharmacol 460:155–161PubMed
172.
Schulz R, Rose J, Martin C, Brodde O-E, Heusch G (1993) Development of short-term hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 88:684–695PubMed
173.
Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE, Singer M, Pietropaoli P (2006) Preconditioning effects of levosimendan in coronary artery bypass grafting – a pilot study. Br J Anaesth 96:694–700PubMed
174.
Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, Buemi M (2000) Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401:349–356PubMed
175.
Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE (2005) Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100:187–197PubMed
176.
Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE (2004) Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 99:173–182PubMed
177.
Cai Z, Manalo D, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108 :79–85PubMed
178.
Rui T, Fenf Q, Lei M, Peng T, Zhang J, Xu M, Dale Abel E, Xenocostas A, Kvietys PR (2005) Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65:719–727PubMed
179.
Shinmura K, Kodani E, Xuan Y-T, Dawn B, Tang X-T, Bolli R (2003) Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol 41:1183–1194PubMed
180.
Przyklenk K, Heusch G (2003) Late preconditioning against myocardial stunning. Does aspirin close the “second window” of endogenous cardioprotection?. J Am Coll Cardiol 41:1195–1197PubMed
181.
Clerk A, Sugden PH (2006) Inflame my heart (by p38-MAPK). Circ Res 99:455–458PubMed
182.
Niavi M, Lee P, Khaper N, Lin P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94:1543–1553
183.
Mann DL (2003) Stress-activated cytokines and the heart. Annu Rev Physiol 65:81–101PubMed
184.
Taqueri VR, Mitchell RN, Lichtman AH (2006) Protecting the Pump: controlling myocardial inflammatory responses. Annu, Rev. Physiol. 68:67–95
185.
Fan G-C, Yuan Q, Song G, Wang Y, Chen G, Qian J, Zhou X, Lee Y, Ashraf M, Kranias E (2006) Small hear-shock protein Hsp20 attenuates β-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1. Circ Res 99:1233–1242PubMed
186.
Iyer VS, Canty Jr JM (2005) Regional desensitization of β-adrenergic receptor signaling in swine with chronic hibernating myocardium. Circ Res 97:789–795PubMed
187.
Tang T, Chin Lai N, Roth DM, Drumm J, Guo T, Lee K-W, Han P-L, Dalton N, Gao MH (2006) Adenylyl cyclase type V deletion increases basal left ventricular function and reduces left ventricular contractile responsiveness to β-adrenergic stimulation. Basic Res Cardiol 101:117–126PubMed
188.
Leineweber K, Bohm M, Heusch G (2006) Cyclic adenosine monophosphate in acute myocardial infarction with heart failure. Slayer Savior? Circulation 114:365–367
189.
Cokkinos D.V (2002) Preconditioning – a paradigm of yin and yang. Hell J Cardiol 43:179–182
190.
Menon B, Krishnamurthy P, Kaverina E, Johnson J, Ross R, Singh M, Singh K (2006) Expression of the cytoplasmic domain of β1 integrin induces apoptosis in adult rat ventricular myocytes 9ARVM) via the involvement of caspase-8 and mitochondrial death pathway. Basic Res Cardiol 101:485–493PubMed
191.
Kim Y-K, Suarez J, Hu Y, et al (2006) Deletion of the inducible 70-kDa heat shock protein genes in mice impairs cardiac contractile function and calcium handling associated with hypertrophy. Circulation 113:2589–2597PubMed
192.
Pantos C, Xinaris C, Mourouzis I, Malliopoulou V, Kardami E, Cokkinos DV (2006) Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: Potential therapeutic implications in reversing cardiac remodeling? Mol Cell Biochem 297:65–72PubMed
193.
Frantz S, Brandes R, Hu K, Rammelt K, Wolf J, Scheuermann h, Ertl G, Bauersachs J (2006) Left ventricular remodeling after myocardial infarction in mice with targeted deletion of the NADPH oxidase subunit gp91PHOX. Basic Res Cardiol 101:127–132PubMed
194.
Shiomi T, Tsutsui H, Matsusaka H, et al (2004) Overexopression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 109:544–549PubMed
195.
Zhang G-X, Kimura S, Nishiyama A, Shokoji T, Rahman M, Abe Y (2004) ROS during the acute phase of ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 43:117–124PubMed
196.
Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, Hasegawa H, Akazawa H, Mizukami M, Nagai R, Komuro I (2001) Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun 289:901–907PubMed
197.
Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y (1995) Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin Invest 96:438–446PubMedCrossRef
198.
Bax JJ, Abraham T, Barold S et al (2005) Cardiacresynchronization therapy: Issues during and after device implantation and unresolved questions. J Am Coll Cardiol 46:2168–2182PubMed
199.
Birks E, Tansley P, Hardy J, George R, Bowles C, Burke M, Banner N, Khaghani A, Yacoub M (2006) Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355:1873–1884PubMed
200.
Jiang S, Haider H, Idris N, Salim A, Ashraf M (2006) Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 99:776–784PubMed
201.
Klepzig H, Kober G. Matter C, Luus H, Scheneider H, Boedeker KH, Kiowski W, Amman FW, Gruber D, Harris S, Burger W (1999) Sulfonylureas and ischemic preconditioning. Eur Heart J 20:439–446PubMed
202.
Weinberg EO, Scherrer- Crosbie M, Picard MH, Nasseri BA, MacGillivray, Cannon J, Lian Q, Bloch KD, Lee RT (2005) Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol-Heart and Circulatory Physiology 288:H1802–H1809
203.
Von Haehling S, Anker SD (2005) Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart 91:1–2
204.
Communal C, Colucci WS (2005) The control of cardiomyocyte apoptosis via the β-adrenergic signaling pathways. Arch Mal Coeur 98:236–241PubMed
205.
O’Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, Hennekens CH (1989) An overview of randomized trials of rehabilitationm with exercise after myocardial infarction. Circulation 80:234–245PubMed
206.
Bellardinelli R, Georgiou D, Cianci G, Purcaro A (1999) Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effect on functional capacity, quality of life, and clinical outcome. Circulation 99:1173–1182
207.
Adamopoulos S, Parissis J, Karatzas D et al (2002) Physical training modulated proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. Am Coll Cardiol 29:653–663
208.
Freimann S, Scheinowitz, Yekutieli D, Feinberg MS, Eldar M, Kessler –Icekson G (2005) Prior exercise training improves the outcome of acute myocardial infarction in the rat: Heart structure, funation, and gene expression. J Am Coll Cardiol 45:931–938PubMed
209.
Ignarro LJ, Balestrieri, Napoli C (2007) Nutrition, physical activity and cardiovascular disease. Cardiovasc Res 73:326–340PubMed
210.
Kardami Elissavet, Detillieux KA, Jimenex SK, Cattini PA (2006) Fibroblast growth factor-2. In: Cokkinos DV, Pantos C, Heusch G, Taegthmeyer H (eds) Myocardial ischemia. Springer Sciences and Business Media Inc, New York, pp 144–166
211.
Kloner RA, Rezkalla SH (2004) Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J Am Coll Cardiol 44:276–286PubMed
212.
Maeng M, Mortensen UM, Kristensen J, Kristiansen SB, Andersen HR (2006) Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. Basic Res Cardiol 101:61–68PubMed
Metadata
Title
Myocardial protection in man—from research concept to clinical practice
Authors
Dennis V. Cokkinos
Costas Pantos
Publication date
01-12-2007
Published in
Heart Failure Reviews / Issue 3-4/2007
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-007-9030-5

Other articles of this Issue 3-4/2007

Heart Failure Reviews 3-4/2007 Go to the issue

OriginalPaper

Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction

OriginalPaper

Cardioprotection in females: a role for nitric oxide and altered gene expression

OriginalPaper

Signaling pathways in ischemic preconditioning

Foreword

Foreword

OriginalPaper

Protection of the abnormal heart

OriginalPaper

HDL and its sphingosine-1-phosphate content in cardioprotection

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits